Stifel Nicolaus Has Lowered Expectations for Health Catalyst (NASDAQ:HCAT) Stock Price

Health Catalyst (NASDAQ:HCAT) had its price objective decreased by equities researchers at Stifel Nicolaus from $10.00 to $5.00 in a report issued on Thursday,Benzinga reports. The brokerage currently has a “hold” rating on the stock. Stifel Nicolaus’ price objective points to a potential upside of 20.80% from the stock’s previous close.

A number of other equities analysts also recently issued reports on HCAT. Stephens reiterated an “equal weight” rating and set a $7.00 price target on shares of Health Catalyst in a research note on Thursday. Piper Sandler cut their target price on Health Catalyst from $12.00 to $8.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 11th. Citigroup decreased their price target on Health Catalyst from $10.50 to $10.00 and set a “buy” rating for the company in a report on Friday, January 10th. KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 price objective on the stock in a research note on Wednesday, January 8th. Finally, Royal Bank of Canada reduced their target price on shares of Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating for the company in a research note on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $9.55.

Health Catalyst Stock Down 16.2 %

HCAT traded down $0.80 during trading on Thursday, hitting $4.14. 528,697 shares of the company’s stock were exchanged, compared to its average volume of 769,911. Health Catalyst has a fifty-two week low of $3.76 and a fifty-two week high of $9.24. The stock has a market cap of $251.85 million, a P/E ratio of -3.07 and a beta of 1.34. The business’s 50 day moving average is $6.09 and its two-hundred day moving average is $7.26. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Insiders Place Their Bets

In related news, insider Linda Llewelyn sold 6,441 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $5.43, for a total transaction of $34,974.63. Following the sale, the insider now directly owns 85,819 shares in the company, valued at approximately $465,997.17. The trade was a 6.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, General Counsel Benjamin Landry sold 19,268 shares of the firm’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $160,309.76. Following the completion of the transaction, the general counsel now owns 72,250 shares of the company’s stock, valued at approximately $601,120. This represents a 21.05 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 87,610 shares of company stock worth $664,043 over the last 90 days. Corporate insiders own 2.50% of the company’s stock.

Institutional Trading of Health Catalyst

Hedge funds and other institutional investors have recently bought and sold shares of the company. Mackenzie Financial Corp purchased a new position in shares of Health Catalyst during the 4th quarter valued at $248,000. PharVision Advisers LLC purchased a new position in Health Catalyst during the fourth quarter worth about $185,000. Two Sigma Advisers LP increased its stake in Health Catalyst by 72.7% in the 4th quarter. Two Sigma Advisers LP now owns 29,700 shares of the company’s stock worth $210,000 after acquiring an additional 12,500 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Health Catalyst in the 4th quarter valued at about $496,000. Finally, ProShare Advisors LLC boosted its position in shares of Health Catalyst by 52.7% during the 4th quarter. ProShare Advisors LLC now owns 16,854 shares of the company’s stock valued at $119,000 after acquiring an additional 5,815 shares during the last quarter. Institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.